Preview

Пульмонология

Расширенный поиск

Современные подходы к диагностике и терапии легочной гипертензии у пациентов с хронической обструктивной болезнью легких

https://doi.org/10.18093/0869-0189-2009-0-1-90-101

Полный текст:

Об авторе

С. Н. Авдеев
ФГУ НИИ пульмонологии ФМБА России
Россия

Авдеев Сергей Николаевич – д. м. н., проф., руководитель клинического отдела 

105077, Москва, ул 11-я Парковая, 32, к. 4

тел.: (495) 465-74-15 



Список литературы

1. Global Initiative for Chronic Obstructive Lung Diseases (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Publication Number 2701, April 2001: 1–100. Updated 2007.

2. Weitzenblum E., Hirth C., Ducolone A. et al. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981; 36: 752–758.

3. Zielinski J., MacNee W., Wedzicha J. et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch. Chest Dis. 1997; 52: 43–47.

4. Simonneau G., Galie N., Rubin L.J. et al. Clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 2004; 43 (12, suppl. S): 5S–12S.

5. Weitzenblum Е., Demedts M. Treatment of pulmonary hypertension in chronic obstructive pulmonary disease. Eur. Respir. Mon. 1998, 7: 180–188.

6. Hida W., Tun Y., Kikuchi Y. et al. Pulmonary hypertension in patients with chronic obstructive pulmonary disease: recent advances in pathophysiology and management. Respiration 2002; 7: 3–13.

7. World Health Organization. Chronic cor pulmonale: a report of the expert committee. Circulation 1963; 27: 594–598.

8. Fishman A.P. State of the art: chronic cor pulmonale. Am. Rev. Respir. Dis. 1976; 114: 775–794.

9. Weitzenblum E. Chronic cor pulmonale. Heart 2003; 89: 225–230.

10. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1994; 150: 833–852, 1158–1168.

11. Thabut G., Dauriat G., Stern J.B. et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127: 1531–1536.

12. Chaouat A., Bugnet A.S., Kadaoui N. et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2005; 172: 189–194.

13. Burrows B., Kettel L.J., Niden A.H. et al. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N. Engl. J. Med. 1972; 286: 912–918.

14. Scharf S.M., Iqbal M., Keller C. et al. Hemodynamic characterization of patients with severe emphysema. Am. J. Respir. Crit. Care Med. 2002; 166: 314–322.

15. Rich S., Dantzker D.R., Ayres S.M. et al. Primary pulmonary hypertension. A national prospective study. Ann. Intern. Med. 1987; 107: 216–223.

16. Burrows B., Fletcher C.M., Heard B.E. et al. Clinical types of chronic obstructive lung disease in London and in Chicago: a study of 100 patients. Am. Rev. Respir. Dis. 1964; 90: 14–27.

17. Kessler R., Faller M., Fourgaut G. et al. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 159: 158–164.

18. Harris P., Heath D. Normal variations in pressure and flow. In: Harris P., Heath D., eds. The human pulmonary circulation. 3rd ed. Edinburgh: Churchill Livingstone; 1986: 149–160.

19. Von Euler U., Lijestrand G. Observations on the pulmonary arterial blood pressure in cat. Acta Physiol. Scand. 1946; 12: 301–320.

20. Weitzenblum E., Sautegeau A., Ehrrhart M. et al. Longterm course of pulmonary arterial pressure in patients with chronic obstructive pulmonary disease. Am. Rev. Respir. Rev. 1984; 130: 993–998.

21. Bergofsky E.H., Holtzman S. A study of the mechanisms involved in the pulmonary arterial pressor response to hypoxia. Circ. Res. 1967; 20: 506–519.

22. Naeije R. Pulmonary hypertension and right heart failure in COPD. Monaldi Arch. Chest Dis. 2003; 59: 250–253.

23. Dinh-Xuan A.T., Higenbottam T., Clelland C. et al. Impairment of endothelium-dependent pulmonary artery relaxation in chronic obstructive pulmonary disease. N. Engl. J. Med. 1991; 324: 1539–1547.

24. Le Cras T.D., McMurtry I.F. Nitric oxide production in the hypoxic lung. Am. J. Physiol. 2001; 280: L575–L582.

25. Zieche R., Petkov V., Williams J. et al. Lipopolysaccharide and interleukin 1 augment the effects of hypoxia and inflammation in chronic obstructive pulmonary disease. Proc. Natl. Acad. Sci. USA 1996; 93: 12478–12483.

26. Barberà J.A., Peinado V.I., Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 892–905.

27. Cherniaev A., Samsonova M., Avdeev S., Bazarov D. Pulmonary vascular remodeling in COPD versus bronchial asthma. Eur. Respir. J. 2003; 22 (suppl. 45): 82s.

28. Fessler H.E. Heart-lung interactions: applications in the critically ill. Eur. Respir. J. 1997; 10: 226–237.

29. Nakamura A., Kasamatsu N., Hashizume I. et al. Effects of hemoglobin on pulmonary arterial pressure and pulmonary vascular resistance in patients with chronic emphysema. Respiration 2000; 67: 502–506.

30. Defouilloy C., Teiger E., Sediame S. et al. Polycythemia impairs vasodilator response to acetylcholine in patients with chronic hypoxemic lung disease. Am. J. Respir. Crit. Care Med. 1998; 157: 1452–1460.

31. Weitzenblum Е., Chaouat А. Hypoxic pulmonary hypertension in man: what minimum daily duration of hypoxaemia is required? Eur. Respir. J. 2001; 18: 251–253.

32. Lee-Chiong T.L., Matthay R.A. The heart in the stable COPD patient. In: Similowski T., Whitelaw W.A., Derenne J.P., eds. Clinical management of chronic obstructive pulmonary disease. New York: Marcel Dekker; 2002: 475–532.

33. Baudouin S.V. Oedema and cor pulmonale revisited. Thorax 1997; 52: 401–402.

34. Hill N.S. The cardiac exam in lung disease. Clin. Chest Med. 1987; 8: 273–285.

35. Matthay R.A., Schwarz M.I., Ellis J.H. et al. Pulmonary artery hypertension in chronic obstructive pulmonary disease: determination by chest radiography. Invest. Radiol. 1981; 16: 95–100.

36. Tan R.T., Kuzo R., Goodman L.R. et al. Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Medical College of Wisconsin Lung Transplant Group. Chest 1998; 113: 1250–1256.

37. Incalzi R.A., Fuso L., De Rosa M. et al. Electrocardiographic signs of chronic cor pulmonale: A negative prognostic finding in chronic obstructive pulmonary disease. Circulation 1999; 99: 1600–1605.

38. Klinger J.R., Hill N.S. Right ventricular dysfunction in chronic obstructive pulmonary disease: evaluation and management. Chest 1991; 99: 715–723.

39. Naeije R., Tobricki A. More on the noninvasive diagnosis of pulmonary hypertension: Doppler echocardiography revisited. Eur. Respir. J. 1995; 8: 1445–1449.

40. Matthay R.A., Berger H.J. Noninvasive assessment of right and left ventricular function in acute and chronic respiratory failure. Crit. Care Med. 1983; 11: 329–338.

41. Jardin F., Dubourg O., Bourdarias J.P. Echocardiographic pattern of acute cor pulmonale. Chest 1997; 111: 209–217.

42. Louie E.K., Rich S., Levitsky S., Brundage B.H. Doppler echocardiographic demonstration of the differential effects of right ventricular pressure and volume overload on left ventricular geometry and filling. J. Am. Coll. Cardiol. 1992; 19: 84–90.

43. Kitabatake A., Inoue M., Asao M. et al. Noninvasive evaluation of pulmonary hypertension by a pulsed doppler technique. Circulation 1983; 68: 302–309.

44. Burghuber O.C., Brunner C.H., Scherk P., Weissel M. Pulsed Doppler echocardiography to assess pulmonary artery hypertension in chronic obstructive pulmonary disease. Monaldi Arch. Chest Dis. 1993; 48: 121–125.

45. Burgess M.I., Mogulkoc N., Bright-Thomas R.J. et al. Comparison of echocardiographic markers of right ventricular function in determining prognosis in chronic pulmonary disease. J. Am. Soc. Echocardiogr. 2002; 15: 633–639.

46. Yock P.G., Popp R.L. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 1984; 70: 657–662.

47. Tramarin R., Torbicki A., Marchandise B. et al. Doppler echocardiographic evaluation of pulmonary artery pressure in chronic obstructive pulmonary disease. Eur. Heart J. 1991; 12: 103–111.

48. Higham M.A., Dawson D., Joshi J. et al. Utility of echocardiography in assessment of pulmonary hypertension secondary to COPD. Eur. Respir. J. 2001; 17: 350–355.

49. Matsuyama W., Ohkubo R., Michizono K. et al. Usefulness of transcutaneous Doppler jugular venous echo to predict pulmonary hypertension in COPD patients. Eur. Respir. J. 2001; 17: 1128–1131.

50. Kunichika N., Miyahara N., Harada M., Tanimoto M. Respiratory variation in superior vena cava flow in patients with chronic obstructive pulmonary disease: Estimation of pulmonary hypertension using Doppler flow index. J. Am. Soc. Echocardiogr. 2002; 15: 1165–1169.

51. Tei C., Dujardin K.S., Hodge D.O. et al. Doppler echocardiographic index for assessment of global right ventricular function. J. Am. Soc. Echocardiogr. 1996; 9: 838–847.

52. Turnbull L.W., Ridgeway J.P., Biernacki W. et al. Assessment of the right ventricle by magnetic resonance imaging in chronic obstructive lung disease. Thorax 1990; 45: 597–601.

53. Kruger S., Haage P., Hoffmann R. et al. Diagnosis of pulmonary arterial hypertension and pulmonary embolism with magnetic resonance angiography. Chest 2001; 120: 1556–1561.

54. Saito H., Dambara T., Aiba M. et al. Evaluation of cor pulmonale on a modified short-axis section of heart by magnetic resonance imaging. Am. Rev. Respir. Dis. 1992; 146: 1576–1581.

55. Chemla D., Castelain V., Herve P. et al. Haemodynamic evaluation of pulmonary hypertension. Eur. Respir. J. 2002; 20: 1314–1331.

56. Raeside D.A., Brown A., Patel K.R. et al. Ambulatory pulmonary artery pressure monitoring during sleep and exercise in normal individuals and patients with COPD. Thorax 2002; 57: 1050–1053.

57. Yoshimura M., Yasue H., Okumura K. et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993; 87: 464–469.

58. Doust J.A., Pietrzak E., Dobson A. et al. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. Br. Med. J. 2005; 330: 625.

59. Maisel A.S., Koon J., Krishnaswamy P. et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am. Heart J. 2001; 141: 367–374.

60. Kruger S., Graf J., Kunz D. et al. Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J. Am. Coll. Cardiol. 2002; 40: 718–722.

61. Leuchte H.H., Heurohr C., Baumgartner R.A. et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2004; 170: 360–365.

62. Leuchte H.H., Holzapfel M., Baumgartner R.A. et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J. Am. Coll. Cardiol. 2004; 43: 764–770.

63. Leuchte H.H., Baumgartner R.A., Nounou M.E. et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am. J. Respir. Crit. Care Med. 2006; 173: 744–750.

64. Hill N.S., Klinger J.R., Warburton R.R. et al. Brain natriuretic peptide: possible role in the modulation of hypoxic pulmonary hypertension. Am. J. Physiol. 1994; 266: 308–315.

65. Jason P., Keang L.T., Hoe L.K. B-type natriuretic peptide: Issues for the intensivist and pulmonologist. Crit. Care Med. 2005; 33: 2094–2103.

66. Wiedemann H.P., Matthay R.A. Cor pulmonale in chronic obstructive pulmonary disease: circulatory pathophysiology and management. Clin. Chest Med. 1990; 11: 523–539.

67. Cazzola M., Mantero A., Santus P. et al. Doppler echocardiographic assessment of the effects of inhaled long-acting beta2-agonists on pulmonary artery pressure in COPD patients. Pulm. Pharmacol. Ther. 2007; 20: 258–264.

68. Muramoto A., Caldwell J., Albert R.K. et al. Nifedipine dilates the pulmonary vasculature without producing symptomatic systemic hypotension in upright resting and exercising patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1985; 132: 963–966.

69. Agusti A.G.N., Barbera J.A., Roca J. et al. Hypoxic pulmonary vasoconstriction and gas exchange during exercise in chronic obstructive pulmonary disease. Chest 1990; 97: 268–275.

70. Agostoni P., Doria E., Galli C. et al. Nifedipine reduces pulmonary pressure and vascular tone during shortbut not long-term treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1989; 139: 120–125.

71. Konietzko N., Schlehe H., Harich B., Matthys H. Effect of isosorbide dinitrate on hemodynamics and respiration of patients with coronary artery disease and of patients with chronic cor pulmonale. Respiration 1975; 32: 368–377.

72. Федорова Т.А. Хроническое легочное сердце. В кн.: Чучалин А.Г. (ред.). Хронические обструктивные болезни легких. М.; ЗАО "Изд-во "БИНОМ"; СПб.: Невский Диалект; 1998. 192–215.

73. Zielinsky J., Hawrylkiewicz I., Goreika D. et al. Сaptopril effects on pulmonary and systemic hemodynamics in chronic cor pulmonale. Chest 1986; 90: 562–565.

74. Kanazawa H., Okamoto T., Hirata K. et al. Deletion polymorphism in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 162: 1235–1238.

75. Kanazawa H., Hirata K., Yoshikawa J. Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study. Thorax 2003; 58: 629–631.

76. Morrell N.W., Higham M.A., Phillips P.G. et al. Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. Respiratory Research. 2005; 6: 88.

77. Mathur P.N., Powles A.C.P., Pugsley S.O. et al. Effect of digoxin on right ventricular function in severe chronic airflow obstruction. Ann. Intern. Med. 1981; 95: 283–288.

78. Polic S., Rumboldt Z., Dujic Z. et al. Role of digoxin in right ventricular failure due to chronic cor pulmonale. Int. J. Clin. Pharmacol. Res. 1990; 10: 153–162.

79. Salvaterra C.G., Rubin L.J. Investigation and management of pulmonary hypertension in obstructive pulmonary disease. Am. Rev. Respir. Dis. 1993; 148: 1414–1417.

80. Borst M.M., Leschke M., Konig U., Worth H. Repetitive hemodilution in chronic obstructive pulmonary disease and pulmonary hypertension: effects on pulmonary hemodynamics, gas exchange, and exercise capacity. Respiration 1999; 66: 225–232.

81. Neff A.L., Petty T.A. Long-term continuous oxygen therapy in chronic airway obstruction: mortality in relation to cor pulmonale, hypoxia and hypercapnia. Ann. Intern. Med. 1970; 72: 621–626.

82. Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann. Intern. Med. 1980; 93: 391–398.

83. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; i: 681–686.

84. Weitzenblum E., Oswald M., Apprill M. et al. Evoluation of physiological variables in patients with chronic obstructive pulmonary disease before and during long-term oxygen therapy. Respiration 1991; 58: 126–131.

85. Singh S., Evans T.W. Nitric oxide, the biological of the decade: fact or fiction? Eur. Respir. J. 1997; 10: 699–707.

86. Adatia I., Wessel D.L. Therapeutic use of inchaled nitric oxide. Curr. Opin. Pediatr. 1994; 6: 583–590.

87. Pepke-Zaba J., Higgenbottam T.W., Dinnh-Xuan A.T. et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338: 1173–1174.

88. Germann P., Ziesche R., Leitner C. et al. Addition of nitric oxide to oxygen improves cardiopulmonary function in patients with severe COPD. Chest 1998; 114: 29–35.

89. Moinard J., Manier G., Pillet O., Castang Y. Effect of inhaled nitric oxide on hemodynamics and V′a/Q′ inequalities in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1994; 149: 1482–1487.

90. Avdeev S., Tsareva N., Nekludova G., Chuchalin A. Inhaled nitric oxide (iNO) in patients with acute cor pulmonale due to acute exacerbation of chronic obstructive pulmonary disease (COPD) [P1756]. Eur. Respir. J. 2003; 22 (suppl. 45): 269s.

91. Авдеев С.Н., Царева Н.А., Неклюдова Г.В., Чучалин А.Г. Ингаляционный оксид азота при легочной гипертензии у больных с обострением ХОБЛ. Сердеч. недостат. 2003; 5 (21): 251–255.

92. Gibbons G.H. Endothelial function as a determinant of vascular function and structure: A new therapeutic target. Am. J. Cardiol. 1997; 79: 3–8.

93. Vonbank K., Ziesche R., Higenbottam T.W. et al. Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD. Thorax 2003; 58: 289–293.

94. Galie N., Manes A., Branzi A. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. Eur. Respir. J. 2002; 20: 1037–1049.

95. Archer S.L., Mike D., Crow J. et al. A placebo-controlled trial of prostacyclin in acute respiratory failure in COPD. Chest 1996; 109: 750–755.

96. Olschewski H., Ghofrani H.A., Walmrath D. et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am. J. Respir. Crit. Care Med. 1999; 160: 600–607.

97. Ghofrani H.A., Wiedemann R., Rose F. et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895–900.

98. Alp S., Skrygan M., Schmidt W.E. et al. Sildenafil improves hemodynamic parameters in COPD-an investigation of six patients. Pulm. Pharmacol. Ther. 2006; 1: 386–390.

99. Roland M., Bhowmik A., Sapsford R.J. et al. Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax 2001; 56: 30–35.

100. Stolz D., Rasch H., Linka A. et al. A randomised, controlled trial of bosentan in severe COPD. Eur. Respir. J. 2008; 32: 619–628.

101. Sulica R. Clinical response to endothelin receptor antagonists in COPD patients with pulmonary hypertension. In: Proceeding of ATS Congress. San Francisco; 2007.


Для цитирования:


Авдеев С.Н. Современные подходы к диагностике и терапии легочной гипертензии у пациентов с хронической обструктивной болезнью легких. Пульмонология. 2009;(1):90-101. https://doi.org/10.18093/0869-0189-2009-0-1-90-101

For citation:


Avdeev S.N. Current approach to diagnosis and therapy of pulmonary hypertension in patients with chronic obstructive pulmonary disease. PULMONOLOGIYA. 2009;(1):90-101. (In Russ.) https://doi.org/10.18093/0869-0189-2009-0-1-90-101

Просмотров: 73


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)